First data encourage Clinical trials to strengthen hope for vaccine against Covid-19The U.S. biotech company Moderna presents positive interim results. Lonza manufactures the vaccine. Isabel Strassheim25 Kommentare25Kommt soon be a vaccination against Covid-19? The final results of clinical trials could be available by the end of 2020.Photo: Samuel Schalch (Tamedia)
the First results from early clinical Tests for a Covid-19-vaccine are there and they are promising. The immune system of the subjects had been strengthened by the vaccine is equally or still more like that of patients who had recovered from the disease, said the U.S. pharmaceutical company Moderna on Monday.
Eight patients who had received two low-to-medium doses of the vaccine developed neutralizing antibodies, similar to how people after surviving infection with the Coronavirus. The data is still limited and only a small number of the subjects focused. Is headed the study by the U.S.-infection Institute, which is headed by the immunologist Anthony Fauci is.
“I’m thrilled,” says Moderna CEO Stéphane Bancel. He can’t expect any better data.
The potential vaccine, called mRNA-1273 is genbasiert. The method is novel and not yet tested. According to the first results, he has been of the subjects are safe and well taken, the side effects are, therefore, low. In the Phase 1 study, 45 subjects took part, you should demonstrate first and foremost, safety and tolerability. In the study of Phase 2, it then goes to dosage and firm effectiveness. With the recent study of Thousands of subjects globally (Phase 3) will begin in July. The final results could be available by the end of the year.
For Phase 3, larger quantities of the vaccine candidates are needed. These are manufactured by the Swiss biotech company Lonza in the order of Moderna. There is less than a month Moncaf Slaoui from the Board of Directors. The Manager, with Moroccan roots, was appointed at the weekend, US President, Trump to the head of the U.S. vaccine program “Warp Speed”.
0 comment please Login to comment
